Investigation of Pharmacokinetic and Pharmacodynamic Interactions after Coadministration of Nefazodone and Haloperidol

Journal of Clinical Psychopharmacology

Volumn 16, Issue 1, 1996, Pages 26-34

  Barbhaiya, Rashmi H ^a   Shukla, Umesh A ^a   Greene, Douglas S ^a   Breuel, Hans Peter ^b   Midha, Kamal K ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b Bioskin GmbH Berlin   (Germany)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; DRUG METABOLITE; HALOPERIDOL; HYDROXYNEFAZODONE; NEFAZODONE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG POTENTIATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HALF-LIFE; HALOPERIDOL; HUMANS; MALE; PSYCHOMOTOR PERFORMANCE; TRIAZOLES;

EID: 0030046921     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199602000-00005     Document Type: Article

References (20)

1. Feighner JP, Pambakian R, Fowler RC, Boyer WF, D'Amico MF. A comparison of nefazodone, imipramine, placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989;25:219-21.
2. Hyslop DK, Allen LE, Tallor DP. Triazolo antidepressants do not inhibit monoamine oxidase. Drug Rev Res 1988;12:77-9.
3. Eison AS, Eison MS, Torrente JR, Wright RN, Yucca RD. Nefazodene. Preclinical pharmacology of a net antidepressant. Psychopharmacol Bull 1990;26:311-5.
4. Kaul S, Shukla UA, Barbhaiya RH, Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin. Pharmacol 1995;35:830-9.
5. Barbhaiya RH, Shukla UA, Greene DS. Single-dose pharmacokinetics of nefazodone in healthy young, elderly subjects, in subjects with renal or hepatic impairment. Eur J Clin Pharmacol (in press).
6. Barbhaiya RH, Brady ME, Shukla UA, Greene DS. Steady-state pharmacokinetics of nefazodone in subjects with normal, impaired renal function. Eur J Clin Pharmacol (In press).
7. Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH Characterization of the metabolites of the antidepressant drug nefazodone in human urine, plasma. Drug Metab Disp 1994;22:304-11.
8. van Laar MW, van Willigenburg APP, Volkerts ER. Acute and subchronic G effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995;15:30-40.
9. Midha KK, Chakraborty BS, Ganes DA, Hawes EM, Hubbard JW, Keegan DL, Korchinski ED, McKay G. Intersubject variation in the pharmacokinetics of haloperiodol, reduced haloperidol. J Clin Pharmacol 1989;9:98-104.
10. Someya T, Shibasaki M, Noguchi T, Takahashi S, Inaba T. Haloperidol metabolism in psychiatric patients. Importance of glucuronidation and carbonyl reduction. J Clin Psychopharmacol 1992;12:169-74.
11. Llerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L, Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype; increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992;14:92-7.
12. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 1991;31:655-60.
13. Buch A, Shukla U, Pittman K, Barbhaiya R. Pharmacokinetics of nefazodone in extensive, poor metabolizers of dextromethorphan. Pharmacol Res 1993;10:S314.
14. Schmid B, Bircher MD, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism. Co-segregation of oxidative o-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
15. Midha KK, Cooper JK, Hawes EM, Hubbard JW, Korchinski ED, McKay G. An ultrasensitive method for determination of haloperidol, reduced haloperidol by high performance liquid chromatography with coulometric detection. Ther Drug Monit 1988;10:177-83.
16. Franc JE, Duncan GF, Farmen RH, Pittman KA. High-performance liquid Chromatographic method for the determination of nefazodone, its metabolites in human plasma using laboratory robotics. J Chromatogr 1991;570:129-38.
17. Gilbaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982.
18. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley & Sons, 1973:27-33.
19. Gill JL. Design analysis of experiments in the animal, medical sciences. Ames, IA: The Iowa State University Press, 1978:179-82.
20. Young D, Midha KK, Fossler MJ, Hawes EM, McKay G, Korchinski ED. Effect of quinidine on the interconversion kinetics between haloperidol, reduced haloperidpl in humans. Implications for the involvement of cytochrome P450IID6. Eur J Clin Pharmacol 1993;44:433-8.